Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Micronutrients

All Drugs and Chemicals

Bone Density Conservation Agents

Vitamins

Vitamin D

Cholecalciferol

Ergocalciferols

Trace Elements

Hormones

Calcium

Calcium, Dietary

Vitamin D3

Calciferol

Ergocalciferol

Vitamin D2

All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.

All participants were ineligible for the intervention due to sufficient serum 25(OH)D levels at screening/baseline.

Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.

Patricia M Sheean, Ph.D., R.D.

Background: Several clinical trials are underway to investigate if variable forms of vitamin D (D2 vs. D3) prescribed at different doses (10,000-50,000 IUs/week) can improve the side-effects associated with treatment for estrogen receptor positive (ER+) breast cancer, specifically aromatase inhibitors (AIs.) Presumably for generalizability and potential safety purposes, these trials predominantly exclude women with metastatic breast cancer (MBC); a rapidly expanding sector of the cancer survivor population who experience significant treatment-related side-effects. Evaluation of the safety of vitamin D3 supplementation is crucial since supplementation can lead to high calcium and importantly, in lab studies have shown that vitamin D3 affects a gene that increases estrogen production. To assure that vitamin D3 does not affect the clinical effects of anti-estrogen therapies, the effect of vitamin D3 supplements on estrogen production requires an evaluation that further explores and defines its potential role in symptom management for this population.

Objectives: This pilot study will evaluate the feasibility of vitamin D3 supplementation in women with MBC, providing much needed data on the preliminary safety and efficacy of this treatment in this patient population. This study will determine: 1) if weekly supplementation of high dose vitamin D3 increases serum vitamin D levels without adverse effects related to such therapy (primary aim); 2) the effects of vitamin D3 supplementation on symptom management (secondary aim); and 3) if vitamin D3 supplementation is associated with improved inflammation (exploratory aim.)

Methods: This is an 8 week "proof of concept" study to monitor laboratory parameters and to assess potential effects on short-term outcomes. Adult, female patients (\>=18 years) with ER+ MBC (Stage IV) of any race/ethnicity and a history of vitamin D \< 30 mg/dl will be recruited from within and around LUMC. Following current clinical practice guidelines, eligible participants will receive 50,000 IUs of vitamin D3 weekly for 8 weeks. Laboratory values, muscle function and inflammation will be examined pre- and post-supplementation, while symptoms will be assessed at baseline, 4 and 8 weeks post-supplementation. We will assess if increases in vitamin D are associated with clinically significant improvements in symptoms and QOL, and decreased inflammation.

Study Aims

Several clinical trials are underway to investigate if vitamin D2 or D3 provided at various doses (10,000-50,000 IUs/week) can improve the side-effects associated with anti-estrogen therapies, specifically aromatase inhibitors (AIs). However, these current trials use variable forms of vitamin D and predominantly include women with Stage I-III disease, excluding women with metastatic breast cancer. Evaluation of the safety of vitamin D3 supplementation is crucial since supplementation can lead to hypercalcemia and importantly, in vitro studies have shown that vitamin D3 influences the transcription of a gene that increases estrogen production.27,28 To assure that vitamin D3 does not abrogate the clinical effects of anti-estrogen therapies, the effect of vitamin D3 supplementation on estrogen production requires evaluation. Therefore, the overarching goal of this pilot study is to evaluate the safety, feasibility and efficacy of vitamin D3 supplementation in women with MBC. We will address and test the following aims and hypotheses, respectively:

Aim 1: To determine if weekly supplementation of 50,000 IUs of vitamin D3 raises serum levels of 25(OH)D to \>30 mg/dl without adverse effects.

Hypothesis 1: Women who are compliant with vitamin D3 supplementation, as evidenced by normalization (\>30 mg/dl) or increases in their serum 25(OH)D levels, will not experience significant changes in serum calcium, parathyroid hormone or serum estradiol levels.

Aim 2: To determine the effect of vitamin D3 supplementation on symptom management.

Hypothesis 2: Women who achieve serum concentrations of 25 (OH)D ≥30 mg/dl or experience significant increases in 25(OH)D will exhibit improvements in pain, fatigue, sleep, mood, muscle function and overall quality of life.

Exploratory Aim: To explore the mechanistic effects of vitamin D3 supplementation on inflammatory markers and its potential association with symptom management.

Summary: Evidence from studies involving early stage breast cancer participants confirms that musculoskeletal pain, endocrine related symptoms and mood disturbances are commonly associated with breast cancer treatment, particularly hormone deprivation therapies. The high prevalence of vitamin D deficiency/insufficiency among breast cancer survivors is well accepted and further hypothesized to aggravate treatment-related side effects, particularly arthralgias. Women with MBC are excluded from the majority of on-going vitamin D supplementation trials for safety and generalizability purposes. However, novel therapies are continuing to improve and prolong the lives of these women, resulting in a rapidly expansive group of breast cancer survivors. While vitamin D supplementation is prescribed to correct an underlying nutrient deficiency in the clinical context of preserving bone health, emerging evidence suggests it may have more systemic effects. Thus, vitamin D repletion/supplementation has profound potential implications for women with MBC, whose primary goal of treatment is to minimize the side-effects of treatment in support of optimal quality of life. This study reflects a highly innovative, yet simple therapy that could ultimately provide these survivors with a much needed evidence-based supportive care strategies.

Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)

Change in laboratory serum value of 25(OH)D at 8 weeks post-supplementation for participants who received weekly supplementation of 50,000 IUs of vitamin D3. Change is expressed as laboratory serum value of 25(OH)D at 8 weeks minus baseline. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.

Assessment of pain using the Beck Pain Scale at weeks 0 and 8. This is a Likert scale item where a score of 0 corresponds to no pain and a score of 10 corresponds to worst pain. Change is calculated as the worst pain rating at 8 weeks minus the worst pain rating at 0 weeks.Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.

Assessment of fatigue using the Piper Fatigue Scale at weeks 0 and 8. The Piper Fatigue Scale is the average of 22 numeric items, with higher scores indicating greater fatigue \[range of scores: 0-10\]. Change is calculated as the fatigue score at 8 weeks minus fatigue score at 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.

Assessment of mood using the Patient Health Questionnaire 8 (PHQ-8) at weeks 0 and 8. The PHQ-8 ranges from 0-24 with higher scores indicating more distress. Change was assessed as PHQ-8 score at 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.

Assessment of muscle function using a hand dynamometer at weeks 0 and 8. Change in dominant handgrip strength in kilograms was calculated as 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.

Assessment of sleep using the Pittsburgh Sleep Quality Index (PSQI) at weeks 0 and 8. Scores range from 0-21 with higher scores indicating poorer sleep quality. Change was calculated as week 8 minus week 0 PSQI. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.

Assessment of quality of life using the functional assessment of cancer therapy-breast symptoms at weeks 0 and 8. Scores range from 0-40 with higher scores indicating better quality of life.

Change was calculated as week 8 score minus week 0 score. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.

Assessment of quality of life using the functional assessment of cancer therapy- endocrine symptoms at weeks 0 and 8. Scores range from 0-76 with higher scores indicating better quality of life. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.

Loyola University

Research Associate

Enrolled women with serum 25 (OH)D less than 30 ng/ml received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks

Intervention

Enrolled women without serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention.

No Intervention

Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention.

No Cholecalciferol

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

Race/Ethnicity

Race/Ethnicity, Customized

United States

Region of Enrollment

Employment status

Body mass index

Stage IV at diagnosis

Duration of metastatic breast cancer

Metastatic sites

The Eastern Cooperative Oncology Group Performance status describes patients' level of functioning, where higher scores indicate lower levels of functioning.

Eastern Cooperative Oncology Group

Radiation therapy for metastates

Surgery for breast cancer

Serum 25(OH)D

Patricia Sheean

The null hypothesis is that there is 0 change in serum 25(OH)D from week 0 to week 8.

Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks.

1 participant who initiated supplementation of cholecalciferol did not have laboratory serum value of 25(OH)D at week 8. Follow up laboratory and/or questionnaire data were not collected for women in the 'no cholecalciferol' arm.

Change in Serum 25(OH)D

The null hypothesis is that there is 0 change in worst pain rating from week 0 to week 8.

All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.

Cholecalciferol: Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.

Change in Worst Pain Rating From the Beck Pain Scale

The null hypothesis is that there is 0 change in fatigue score from week 0 to week 8.

1 participant who initiated supplementation of cholecalciferol did not have assessment of fatigue at week 8. Follow up laboratory and/or questionnaire data were not collected for women in the 'no cholecalciferol' arm.

Change in Fatigue

The null hypothesis is that there is 0 change in mood score from week 0 to week 8.

1 participant who initiated supplementation of cholecalciferol did not have assessment of mood at 8 weeks. Follow up laboratory and/or questionnaire data were not collected for women in the 'no cholecalciferol' arm.

Change in Mood

The null hypothesis is that there is 0 change in dominant handgrip strength from week 0 to week 8.

1 participant who initiated supplementation of cholecalciferol did not have hand dynamometer data at 8 weeks. Follow up laboratory and/or questionnaire data were not collected for women in the 'no cholecalciferol' arm.

Change in Muscle Function

The null hypothesis is that there is 0 change in sleep quality assessment from week 0 to week 8.

1 participant who initiated supplementation of cholecalciferol did report the Pittsburgh Sleep Quality Index at week 8. Follow up laboratory and/or questionnaire data were not collected for women in the 'no cholecalciferol' arm.

Change in Sleep Quality Assessment

The null hypothesis is that there is 0 change in functional assessment of cancer therapy-breast score from week 0 to week 8.

1 participant who initiated supplementation of cholecalciferol did not have the Functional assessment of cancer therapy-breast at 8 weeks. Follow up laboratory and/or questionnaire data were not collected for women in the 'no cholecalciferol' arm.

Change in Functional Assessment of Cancer Therapy-breast

The null hypothesis is that there is 0 change in functional assessment of cancer therapy-endocrine score from week 0 to week 8.

1 participant who initiated supplementation of cholecalciferol did not have the Functional assessment of cancer therapy-endocrine at 8 weeks. Follow up laboratory and/or questionnaire data were not collected for women in the 'no cholecalciferol' arm.

Spots Global Cancer Trial Database for adult women

Every month we try and update this database with for adult women cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for adult women

Every month we try and update this database with for adult women cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for adult women cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.